Promis Diagnostics engages in developing biomarkers and developing highly specific detection methods. Their tests are based on proprietary epigenetic and other molecular technologies that identify methylation markers for several cancers, enabling healthcare institutes to improve patient outcomes.
Partial Data by Infogroup (c) 2024. All rights reserved.